KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Net Income (2016 - 2025)

Historic Net Income for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $3.1 billion.

  • Gilead Sciences' Net Income rose 14357.54% to $3.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 billion, marking a year-over-year increase of 707699.12%. This contributed to the annual value of $479.0 million for FY2024, which is 9146.47% down from last year.
  • Per Gilead Sciences' latest filing, its Net Income stood at $3.1 billion for Q3 2025, which was up 14357.54% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Net Income registered a high of $3.1 billion during Q3 2025, and its lowest value of -$4.2 billion during Q1 2024.
  • In the last 5 years, Gilead Sciences' Net Income had a median value of $1.5 billion in 2021 and averaged $1.2 billion.
  • Its Net Income has fluctuated over the past 5 years, first surged by 810000.0% in 2023, then plummeted by 52388.21% in 2024.
  • Gilead Sciences' Net Income (Quarter) stood at $376.0 million in 2021, then soared by 334.31% to $1.6 billion in 2022, then dropped by 13.29% to $1.4 billion in 2023, then increased by 25.85% to $1.8 billion in 2024, then skyrocketed by 71.27% to $3.1 billion in 2025.
  • Its Net Income stands at $3.1 billion for Q3 2025, versus $2.0 billion for Q2 2025 and $1.3 billion for Q1 2025.